Lyndra Therapeutics Announces Notice of Allowance on Patent Covering Long-acting Pill

Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for intellectual property (IP) related to Lyndra’s ultra-long-acting oral drug delivery system.

Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, today announced a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for intellectual property (IP) related to Lyndra’s ultra-long-acting oral drug delivery system. This indicates that the patent application has cleared internal review and is pending issuance.

“Our scientific co-founders’ work while at MIT is foundational to our success as a company and an important cornerstone of our growing intellectual property portfolio. We are pleased with the Notice of Allowance as we continue our journey toward approval of the ultra-long-acting dosage form,” said Amy Schulman, CEO and co-founder of Lyndra Therapeutics. “We are committed to changing how people will take medicine in the future, and a broad and strong intellectual property portfolio protects our investment in this important mission.”

The Notice of Allowance relates to U.S. patent application No. 15/317,566, entitled “Residence Structures and Related Methods.” Lyndra is the exclusive licensee of this IP from the Massachusetts Institute of Technology (MIT). The license is a key part of Lyndra’s IP portfolio, which broadly covers Lyndra’s gastric residence technology and products and includes additional patent applications assigned to MIT and Brigham and Women’s Hospital as well as Lyndra’s own patent applications.

“When we first developed the technology behind the ultra-long-acting oral dosage platform, we envisioned patient benefits across many chronic and infectious diseases. With that technology, the team at Lyndra is close to achieving this vision, starting with diseases where patient need is greatest and health system costs are unsustainable,” said Dr. Robert Langer, Institute Professor at MIT, co-founder of Lyndra Therapeutics and co-inventor on the USPTO application.

Lyndra recently released positive results from a pharmacokinetics (PK) study of its ultra-long-acting oral dosage form, for the first time showing it’s possible to convert a once-daily therapy into a weekly dosage.

About Lyndra Therapeutics’ Platform

Lyndra Therapeutics’ orally administered dosage form is designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. Taking a single, long-acting pill weekly instead of daily or more often can improve medication adherence and health outcomes while reducing burdens on individuals and their caregivers. Inside a familiar capsule is a star-shaped formulation with active pharmaceutical ingredients that are released consistently over time. The formulation, which is designed to open once inside the stomach, eventually exits safely via the gastrointestinal tract, like undigested food.

About Lyndra Therapeutics

Lyndra Therapeutics aims to improve healthcare outcomes through oral, ultra-long-acting, sustained-release therapies that change how people take medicines. Instead of taking medications daily or more frequently, doses would be administered weekly or monthly, improving medication adherence for better health outcomes and lower healthcare costs. Delivering controlled amounts of medicine would also reduce side effects and improve drug efficacy. For more information, visit the company’s website www.lyndra.com.

Contacts

Ken DiCienzo
781-351-1519
lyndra@greenough.biz